TOKYO - Around 90 percent of those who received the vaccine developed by U.S. pharmaceutical giant Pfizer Inc. were found to have antibodies against the various COVID-19 variants detected in Japan, a university study showed Wednesday.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
